Kiniksa Pharmaceuticals, Ltd.
Records under this name other than the patents Kiniksa Pharmaceuticals, Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Showing 1 to 7 of 7 · Back to Kiniksa Pharmaceuticals, Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,464,830 | Treatment of Inflammatory Conditions by Delivery of INTERLEUKIN-1 Receptor Antagonist Fusion Protein Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,844,765 | Treatment of Inflammatory Conditions by Delivery of INTERLEUKIN-1 Receptor Antagonist Fusion Protein Formerly held In force · Low confidence | In force | Low confidence | |
| US 11,944,666 | Treatment of Inflammatory Conditions by Delivery of INTERLEUKIN-1 Receptor Antagonist Fusion Protein Formerly held In force · Low confidence | In force | Low confidence | |
| US 12,201,673 | Treatment of Inflammatory Conditions by Delivery of INTERLEUKIN-1 Receptor Antagonist Fusion Protein Formerly held In force · Low confidence | In force | Low confidence | |
| US 11,026,997 | Treatment of Inflammatory Conditions by Delivery of INTERLEUKIN-1 Receptor Antagonist Fusion Protein Formerly held In force · High confidence | In force | High confidence | |
| US 12,234,294 | Pharmaceutical composition of a humanized anti-CD40 antibody Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,325,979 | Treatment of cytokine release syndrome with GM-CSF antagonists Formerly held Lapsed on the fee record Ended May 10, 2026 · USPTO record | Lapsed on the fee record | Ended May 10, 2026 | USPTO record |